Kris Mahadeo (@mahadeokris) 's Twitter Profile
Kris Mahadeo

@mahadeokris

Professor. Chief, Duke Pediatric Transplant and Cellular Therapy. Board of Directors: Grace Children’s Foundation. Views are my own and not medical advice.

ID: 1469097421032599556

linkhttps://www.gifts.duke.edu/dch?designation=391000714 calendar_today10-12-2021 00:11:49

552 Tweet

403 Takipçi

528 Takip Edilen

NMDP (@nmdp_org) 's Twitter Profile Photo

Welcome to our 2025 mentees to the NMDP Cord Blood Immersion Program! Over two weeks, these clinicians will gain hands-on experience as our pediatric transplant mentees train at Duke University with Dr. Joanne Kurtzberg and adult transplant mentees at University of Colorado with Dr. Jonathan Gutman.

Welcome to our 2025 mentees to the NMDP Cord Blood Immersion Program! Over two weeks, these clinicians will gain hands-on experience as our pediatric transplant mentees train at <a href="/DukeU/">Duke University</a> with Dr. Joanne Kurtzberg and adult transplant mentees at <a href="/CUSystem/">University of Colorado</a> with Dr. Jonathan Gutman.
Kris Mahadeo (@mahadeokris) 's Twitter Profile Photo

Wonderful morning with the SBTMO Thank you for thoughtful discussion on how we can improve outcomes for children with relapsed ALL around the globe.

Claire Horgan (@claire_p_horgan) 's Twitter Profile Photo

Cord blood #EBMT25 Great talk from Rob Wynn BMTU/Ward 79 Stem Cell Unit updating us all about cord blood transplant in paediatrics. Less relapse in malignant disease, better chimerism & less chronic GVHD

Cord blood #EBMT25 
Great talk from <a href="/rob_wynn_TdF/">Rob Wynn</a> <a href="/RMCH_BMTU/">BMTU/Ward 79 Stem Cell Unit</a> updating us all about cord blood transplant in paediatrics. Less relapse in malignant disease, better chimerism &amp; less chronic GVHD
Blood Journal (@bloodjournal) 's Twitter Profile Photo

Schematic overview of the potential therapeutic benefits of a novel epigenetic treatment strategy for T-ALL. ow.ly/FexL50Vq84O #lymphoidneoplasia

Schematic overview of the potential therapeutic benefits of a novel epigenetic treatment strategy for T-ALL. ow.ly/FexL50Vq84O #lymphoidneoplasia
Transplantation and Cellular Therapy Journal (@astct_journal) 's Twitter Profile Photo

This study shows that combining MRD and IKZF1 deletion refines risk stratification in adult B-ALL, identifying standard, intermediate and high-risk groups. #AlloHSCT improved outcomes in higher-risk patients. Read the full study: astctjournal.org/article/S2666-…

This study shows that combining MRD and IKZF1 deletion refines risk stratification in adult B-ALL, identifying standard, intermediate and high-risk groups. #AlloHSCT improved outcomes in higher-risk patients. Read the full study: astctjournal.org/article/S2666-…
ASTCT (@astct) 's Twitter Profile Photo

Join the Cord Blood SIG on May 7 for an overview of recent developments in cord blood transplant for heme malignancies. The focus of this webinar will be on manipulated graft sources and insights from real world use of expanded cord blood. Register now: ow.ly/Fmn350VF2bG

Join the Cord Blood SIG on May 7 for an overview of recent developments in cord blood transplant for heme malignancies. The focus of this webinar will be on manipulated graft sources and insights from real world use of expanded cord blood. Register now: ow.ly/Fmn350VF2bG
ASTCT (@astct) 's Twitter Profile Photo

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in 4 week-long observership at the University of California Health - Irvine. 📆 Deadline to apply: Friday, June 13 ow.ly/Ih0650VK0vn

Applications are open for the 2026 International Trainee Observership Program. One international trainee from a low/mid-income country will participate in 4 week-long observership at the <a href="/UofCAHealth/">University of California Health</a> - Irvine. 

📆 Deadline to apply: Friday, June 13
ow.ly/Ih0650VK0vn
Matteo Di Nardo (@mat_dinardo) 's Twitter Profile Photo

First international consensus statement by ESPNIC, PALISI and The EBMT on the admission and early management of pediatric patients receiving #HSCT and immune effector cell therapy. The Lancet Child & Adolescent Health Kris Mahadeo Krzysztof Kałwak Bambino Gesù thelancet.com/journals/lanch…

First international consensus statement by <a href="/ESPNIC_Society/">ESPNIC</a>, <a href="/PALISInet/">PALISI</a> and <a href="/TheEBMT/">The EBMT</a> on the admission and early management of pediatric patients receiving #HSCT and immune effector cell therapy. <a href="/LancetChildAdol/">The Lancet Child & Adolescent Health</a> <a href="/MahadeoKris/">Kris Mahadeo</a> <a href="/krzysztofkalwak/">Krzysztof Kałwak</a> <a href="/bambinogesu/">Bambino Gesù</a>

thelancet.com/journals/lanch…